Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation (Q44245126)

1 December 2017

title

Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation (English)

1 reference

1 December 2017

0 references

1 reference

Burns LJ

1

1 reference

1 December 2017

Miller W

2

1 reference

1 December 2017

Kandaswamy C

3

1 reference

1 December 2017

DeFor TE

4

1 reference

1 December 2017

MacMillan ML

5

1 reference

1 December 2017

Van Burik JA

6

1 reference

1 December 2017

Weisdorf DJ

7

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Bone Marrow Transplantation

1 December 2017

published in

1 reference

1 December 2017

volume

30

1 reference

1 December 2017

issue

12

1 reference

1 December 2017

page(s)

945-951

1 reference

Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

Non-parametric inference for cumulative incidence functions in competing risks studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

Risk factors for cytomegalovirus infection after human marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

7 January 2021

Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

7 January 2021

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

7 January 2021

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

7 January 2021

Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

7 January 2021

Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

7 January 2021

Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: no evidence of increased incidence in patients receiving unrelated donor grafts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

7 January 2021

CMV antigenemia following bone marrow transplantation: risk factors and outcomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

7 January 2021

Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

7 January 2021

Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703770

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703770

1 reference

1 December 2017

1 reference